Harness the Synergy Between Targeted Therapy and Immunotherapy: What Have We Learned and Where Are We Headed?

Oncotarget - United States
doi 10.18632/oncotarget.21160
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Recent Advances in Pruritus – What We Have Learned and Where Are We Headed

F1000 Medicine Reports`
2010English

Structural MRI of Pediatric Brain Development: What Have We Learned and Where Are We Going?

Neuron
Neuroscience
2010English

Where Have We Been and Where Are We Going?

1998English

Molecular Targeted Agents--Where We Are and Where We Are Going

Chinese Journal of Cancer
2013English

Drug Development for Alzheimer's Disease: Where Are We Now and Where Are We Headed?

The American Journal of Geriatric Pharmacotherapy
2009English

What We Have Learned and How We May Proceed

International Studies in Entrepreneurship
2020English

EuReCa_Serbia: What Have We Learned?

Journal Resuscitatio Balcanica
2019English

Rivaroxaban in Acute Coronary Syndromes: We Have a Compass and an Atlas, but Where Are We Headed?

Journal of the American Heart Association
Cardiovascular MedicineCardiology
2019English

Community Education: Where We Have Been and Where We Are Going

Educational Considerations
1974English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy